Our current study demonstrated that in ERBB2-positive breast cancer, ERRF also plays an important role, as ERRF sensitized such cells to lapatinib treatment, and higher levels of ERRF expression correlated with increased lapatinib sensitivity and better patient survival. The gene discussed is SRARP; the disease is breast carcinoma.